Goltix Norge - norsk - Adama

goltix

adama - metamitron 700 g/kg - ugrasmiddel

Legacy 500 SC Norge - norsk - Adama

legacy 500 sc

adama - diflufenican 500 g/l (42 vikt-%) - ugrasmiddel

Mavrik Norge - norsk - Adama

mavrik

adama - tau-fluvalinat - insektmiddel

Mixin Norge - norsk - Adama

mixin

adama - florasulam 2,5 g/l (0,25 vikt-%) + fluroksypyr-1-metylheptylester 144 g/l (14.2 vikt-%) - ugrasmiddel

Pirimor Norge - norsk - Adama

pirimor

adama - pirimikarb - insektmiddel

Sugammadex Fresenius Kabi Den europeiske union - norsk - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Lunsumio Den europeiske union - norsk - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Kimmtrak Den europeiske union - norsk - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastiske midler - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Topimax 25 mg Norge - norsk - Statens legemiddelverk

topimax 25 mg

paranova as - topiramat - tablett, filmdrasjert - 25 mg

Tecvayli Den europeiske union - norsk - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - multippelt myelom - antineoplastiske midler - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.